| Ticker: MMP | 4350 Executive Drive, Suite 310 | |
| Exchange: American Stock Exchange | San Diego, California 92121 | |
| Industry: Manufacturing | (619) 453-4040 |
| Type of Shares: | Common Shares | Filing Date: | 6/4/96 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 7/10/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $7.00 - $8.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $7.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.60 | |
| Offering Amount: | $18,750,000 | Selling: | $0.30 | |
| Expenses: | $500,000 | Reallowance: | $0.10 | |
| Shares Out After: | 6,295,837 |
| Manager | Tier | Phone |
| National Securities Corp. | Lead Manager | (206) 622-7200 |
| Auditor: KPMG Peat Marwick | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 9/30/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $3.16 |
| Net Income: | -$2.79 | -$1.49 | -$1.37 | Liabilities: | $3.99 |
| EPS: | -$0.87 | -$0.41 | Equity: | -$0.84 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is developing two platform technologies for the prevention and treatment of infectious diseases. The company's proprietary technologies have led to the development of its lead product candidate, Maxamine, which is based on the discovery of an immune system mechanism that may allow certain biological response modifiers, such as cytokines, to achieve their full, antitumor, and aniti-infective potential. In addition, the company is developing MaxVax, a mucosal vaccine carrier/adjuvant technology for application in protective, therapeutic, anti-inflammatory, and gene-based vaccines. The MaxVax technology targets the immune response at the mucosal membranes that represent the body's first line of defense against infections and are the sites where most infectious agents enter the body. Ongoing Phase II human clinical trials using Maxamine for the treatment of acute myelogenous leukemia and malignant melanoma are in progress in Sweden under the Company's sponsorship. |
| Use of Proceeds |
| The company anticipates to use the net proceeds of this offering for research and development, clinical trials, repayment of debt, license fees, working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.